BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Anetumab ravtansine (BAY94-9343)

First Posted Date: 2016-03-02

Last Posted Date: 2021-07-09

Lead Sponsor: Bayer

Target Recruit Count: 54

Registration Number: NCT02696642

18790 - Sun Protection Factor Assay

Not Applicable

Completed

Conditions: Sunscreening Agent

Interventions: Drug: Coppertone (BAY 987516)

First Posted Date: 2016-03-01

Last Posted Date: 2018-12-13

Lead Sponsor: Bayer

Target Recruit Count: 10

Registration Number: NCT02695303

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: VKA (Vitamin K antagonist)

First Posted Date: 2016-02-24

Last Posted Date: 2017-04-05

Lead Sponsor: Bayer

Target Recruit Count: 38831

Registration Number: NCT02690155

Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Vitamin K antagonist
Drug: Dabigatran (Pradaxa)

First Posted Date: 2016-02-22

Last Posted Date: 2017-04-05

Lead Sponsor: Bayer

Target Recruit Count: 56039

Registration Number: NCT02687867

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Vitamin K antagonist
Drug: Apixaban

First Posted Date: 2016-02-22

Last Posted Date: 2017-04-05

Lead Sponsor: Bayer

Target Recruit Count: 18591

Registration Number: NCT02687854

18791 - Sun Protection Factor Assay

Not Applicable

Completed

Conditions: Sunscreening Agent

Interventions: Drug: Coppertone (BAY987517)

First Posted Date: 2016-02-15

Last Posted Date: 2018-12-13

Lead Sponsor: Bayer

Target Recruit Count: 10

Registration Number: NCT02682628

A Multi-Site Evaluation of the Pain Relief, Support, Fit and Comfort From Use of a Custom Knee or Ankle Brace in Persons Suffering From Chronic Ankle or Knee Pain and Instability

Not Applicable

Completed

Conditions: Joint Instability

Interventions: Device: Dr. Scholl's Prototype Ankle Brace
Device: Dr. Scholl's Prototype Knee Brace

First Posted Date: 2016-02-15

Last Posted Date: 2018-12-12

Lead Sponsor: Bayer

Target Recruit Count: 183

Registration Number: NCT02682654

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Phase 1

Completed

Conditions: Drug Interaction
Healthy Volunteers
Pharmacokinetics

Interventions: Drug: Rosuvastatin
Drug: BAY1841788 (ODM-201)

First Posted Date: 2016-02-02

Last Posted Date: 2016-09-08

Lead Sponsor: Bayer

Target Recruit Count: 30

Registration Number: NCT02671097

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

Not Applicable

Completed

Conditions: Bronchiectasis
Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo to Ciprofloxacin DPI (BAYQ3939)

First Posted Date: 2016-01-22

Last Posted Date: 2018-12-19

Lead Sponsor: Bayer

Target Recruit Count: 46

Registration Number: NCT02661438

Stivarga Real Life Evidence in Hungary

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2016-01-15

Last Posted Date: 2018-02-12

Lead Sponsor: Bayer

Target Recruit Count: 400

Registration Number: NCT02656524

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy